Thymosin Alpha-1

What it is

Thymosin Alpha-1 (TA1) is the peptide your thymus makes to train your T cells — and the only one in this wiki with a multi-decade, ~11,000-subject human safety record before it ever hit the peptide community. It’s a 28-amino-acid peptide bioidentical to one your thymus produces naturally, sold pharmaceutically as thymalfasin under the brand name Zadaxin in 30+ countries (not yet FDA-approved in the US). It was first isolated and sequenced in 1977 by Allan Goldstein and Teresa L. Low (Goldstein, Low et al., PNAS 1977;74(2):725–729) — the culmination of thymus-extract work that began in the 1960s in Abraham White’s lab at Albert Einstein College of Medicine, purified from a crude preparation called thymosin fraction 5, in which TA1 turned out to be one of the most biologically active components. (Educators sometimes render the co-author as “Tom Low”; it’s Teresa L. Low.) What makes it interesting is the biology underneath: your thymus, the master training facility for the immune system, starts shrinking around age 1, accelerates at puberty, and is essentially gone by old age — by 70 only ~10% of functional thymic tissue remains, by 78 about 0.5% (the rest replaced by fat). T-cell output halves roughly every 16 years; CD8 killer T cells drop about 9-fold from young adulthood to old age; TCR diversity falls to 20–50% of young-adult baseline after age 60. A 2018 mathematical model fit against 101 cancer types argued that for many cancers, immune-surveillance decline may matter more than DNA-mutation accumulation. That’s the framing worth holding: TA1 is the peptide you reach for when the question is “the drill sergeant who trained my immune army retired 30 years ago — can I get someone to take his place?”

Two more things worth stating up front. First: TA1’s benefits are compensatory, not permanent. Unlike BPC-157 (heal a tendon, the tendon stays healed), TA1 is doing the job a shrinking thymus can no longer do: when you stop, the support fades over weeks. Second: it’s a modulator, not a booster. Same molecule, same dose, opposite effects in different tissues at the same time. That’s a feature, not marketing.

How it works

TA1’s signature is its two-arm, simultaneous, tissue-context-aware mechanism. Most immune drugs do one of two things: turn the system on, or turn it down. TA1 does both at once, and the local tissue environment chooses which arm dominates.

TLR2 arm (wake it up). TA1 binds Toll-like receptor 2, which activates the NF-κB transcription program. This matures dendritic cells (the antigen-presenting traffic controllers), activates natural killer (NK) cells, pushes the response toward TH1 polarization (virus- and abnormal-cell-killing), and drives cytokine production. This is the arm that explains why TA1 helps sluggish immune systems clear viruses (hep B) and respond to vaccines.

TLR9 arm (calm it down). TA1 also binds TLR9, which triggers Type-1 interferon release. Type-1 IFN upregulates IDO (indoleamine 2,3-dioxygenase), which breaks tryptophan down into kynurenines, which generate regulatory T cells (T-regs) — a cascade demonstrated in Romani et al., Blood 2006;108(7):2265–2274 (PMID 16741252), which showed IDO induction by TA1 requires both TLR9 and the type-I interferon receptor. T-regs are the brakes on autoimmunity. This is the arm that explains why TA1 helps in conditions like Hashimoto’s where the immune system is attacking the body’s own tissue.

Accuracy note on the two-arm model. The clean “TLR2 = attack, TLR9 = brake” split is a useful teaching simplification but not literally how the receptors divide up. In the primary work (Romani et al., Blood 2004;103(11):4232–4239, PMID 14982877, and the 2006 paper above), TLR9 actually feeds both arms — it contributes (with TLR2, through the MyD88 adaptor) to the Th1/IL-12 “attack” program and is the receptor required for the IDO/T-reg “brake.” So the honest statement is: TA1 drives Th1 maturation via MyD88-dependent TLR signaling, and separately drives the IDO/T-reg tolerance program via TLR9 + type-I IFN. Local tissue context, not a tidy one-receptor-per-arm wiring, is what determines the net effect. (These mechanisms were first characterized in antifungal Aspergillus/Candida models, then generalized.)

Tissue context is the switch. A 2020 mouse study showed the same molecule at the same dose boosted anti-tumor immunity at a tumor site while simultaneously calming gut inflammation in the same animal. That’s the “modulator, not booster” framing in one experiment.

Additional mechanisms with disease relevance:

• Boosts complement-mediated phagocytosis (fast innate clearance). Beyond the slow, adaptive T-cell education, TA1 also switches on a rapid innate effect: it enhances how quickly macrophages engulf complement-opsonized pathogens, working before the adaptive response has spun up. Shown in human monocyte-derived macrophages by Serafino et al., J Innate Immun 2014;6(1):72–88 (PMID 23797159) — the effect ran predominantly through the complement-receptor (not Fc) pathway, appeared within ~30 minutes, and was microtubule/PKC-dependent. (Strong in-vitro human-cell evidence; not yet a clinical clearance endpoint.)
• Reverses T-cell exhaustion. In chronically ill patients whose T cells have become “exhausted,” TA1 is associated with restored T-cell numbers and reduced exhaustion markers PD-1 and TIM-3 (the molecular “white flags” a worn-out T cell raises). This is the mechanism behind its severe-COVID signal: Liu et al., Clin Infect Dis 2020;71(16):2150–2157 (PMID 32777028) — a retrospective, non-randomized cohort of 76 severe COVID patients — reported mortality 11.1% (TA1) vs 30.0% (untreated), P = 0.044, with reduced PD-1/TIM-3 on CD8+ T cells and the greatest T-cell restoration in the most lymphopenic patients. Real but hypothesis-generating (association in a retrospective cohort, not a controlled efficacy trial).
• Crosses the blood-brain barrier and is reported to calm hyperactive microglia, shifting them from the destructive M1 state to the cleanup-and-repair M2 state, reducing IL-1β / TNF-α / IL-6 and promoting BDNF (one practitioner cites Journal of Neuroscience).
• Resists glucocorticoid suppression of immune cell function — cortisol normally suppresses thymic output; TA1 reportedly restores function even under high glucocorticoid load (one practitioner cites Brain, Behavior, and Immunity).
• Promotes antigen presentation on virally infected cells — makes infected hepatocytes visible to cytotoxic T cells, the mechanism behind hep B clearance.

One practitioner’s metaphor — “a software patch that removes malware and reboots the system” vs. interferon’s “carpet bombing” — captures the precision angle well. One practitioner’ simpler version: TA1 is what the body already does itself when the thymus is working; the synthetic version compensates for a thymus that no longer can.

What the research shows

Human trials: the wins.

• Hepatitis B (foundational pilot): small pilot: 6 of 7 patients cleared the virus on TA1 vs. 1 of 5 on placebo (86% clearance). Larger follow-up trials reported approximately 60% surface-antigen seroconversion — a remarkable number in chronic hep B.
• Hepatitis B/C as interferon replacement — Hepatology Research reported TA1 plus interferon improved sustained virologic response, and one practitioner’s stronger framing is that TA1 can replace interferon entirely (precision targeting vs. carpet-bomb side effects).
• Vaccine enhancement in the elderly: a double-blind placebo-controlled trial showed TA1 enhanced antibody response to the influenza vaccine in elderly subjects; in follow-up, influenza incidence dropped from 19% (vaccine alone) to 6% (vaccine + TA1). At 12 months, 45% of the TA1 group still had protective antibody levels vs. 0% of placebo. This is a flagship “the peptide makes the standard intervention actually work” finding for the immunosenescent population.
• NSCLC (Non-Small-Cell Lung Cancer) 2025: n = 196 patients receiving chemoradiotherapy + immunotherapy; adding TA1 cut death risk by 60% and halved the rate of radiation pneumonitis.
• Gastric cancer 2026: trial reporting 30% of patients had complete tumor disappearance, with zero severe immune-related adverse events.
• Hashimoto’s thyroiditis — Endocrine (2016) reported TA1 re-educated confused T cells, increased T-regs, restored TH1/TH2 balance, and addressed the underlying immune dysregulation rather than just managing symptoms.

Human trials: the loss (and why this article shows it).

The TEST trial (January 2025) was a Phase 3, 1,089-patient, 22-center, double-blind, placebo-controlled trial of TA1 in adult sepsis. Primary endpoint negative. 28-day mortality: 23.4% TA1 vs. 24.1% placebo: essentially identical. But the subgroup signal is the interesting part:

• Patients over 60 trended toward benefit.
• Diabetics showed significant benefit.
• Patients under 60 actually showed harm.

The honest interpretation, given the mechanism: TA1 helps immune systems that are already failing. A 35-year-old with septic shock has an immune system that is hyper-active, not failing — adding a modulator that pushes some arms further up can make things worse. A 70-year-old septic diabetic has an exhausted, dysregulated immune system that responds to the re-education. This is consistent with TA1’s biological role and matters for who should use it.

Cancer-adjuvant data — what the two flagship trials actually show (and one common overstatement). Peptide educators often describe a “large randomized melanoma study” and an “NSCLC survival benefit” as settled wins. The primary literature is more nuanced:

• Melanoma (Maio et al., J Clin Oncol 2010;28(10):1780–1787, PMID 20194853): n = 488, five arms. Median overall survival 9.4 months on the TA1 arms vs 6.6 months control — HR 0.80 (95% CI 0.63–1.02), P = 0.08. That is a favorable trend that did not reach statistical significance. Describing it as “linked TA1 to better survival” overstates it; the honest line is “a promising but non-significant signal.”
• NSCLC (Zhang et al., Chinese Medical Journal 2021, PMID 34732663): a propensity-score-matched analysis of 1,027 matched pairs after R0 resection — 5-year OS 83.3% vs 72.7%, 5-year DFS 77.3% vs 64.7% (both P < 0.0001), adjusted OS HR 0.548. Strongly positive, but retrospective/observational and single-country, so residual confounding is possible. “Propensity-matched analysis” is the correct, appropriately hedged framing.

Animal / preclinical: first-class evidence.

• Neuroprotection — mouse models showing microglial M1→M2 switching, reduced amyloid-β toxicity, reduced tau hyperphosphorylation, promoted autophagy clearing α-synuclein aggregates, and increased T-reg–driven remyelination in MS models.
• Tissue-selective modulation — the 2020 study showing simultaneous opposite effects (anti-tumor + anti-inflammatory) in the same animal — mechanistically the most interesting single experiment in the file.

Where experts read it differently. One practitioner’s framing leans expansive: TA1 as a near-universal immune-rebuild peptide hitting Hashimoto’s, hep B/C, Alzheimer’s, Parkinson’s, MS, cancer survival — including a “survival increase of 89% in lung/breast/prostate cancer” number that we treat with caution: it’s much larger than one practitioner’ more conservative NSCLC 60%-death-risk number (n=196, 2025) and the precise endpoint/sample size needs verification before lifting into customer copy. One practitioner’ framing is the cleaner evidence record — he gives the negative TEST trial equal airtime to the wins, surfaces the under-60 harm signal, and flags the PD-1 contraindication that one practitioner doesn’t mention. Both reads matter. One practitioner is right that the mechanism breadth is unusual and the safety record is real. One practitioner is right that not every claim is well-sourced and the audience for TA1 is narrower than “everyone.”

The autoimmune / Long COVID question. The mechanism for autoimmune diseases (the TLR9 → T-reg arm) and Long COVID (post-viral immune dysregulation) is strong. Human interventional evidence for Long COVID doesn’t yet exist — the rationale is mechanistic, not trial-confirmed. The closest data point is Minutolo et al., Int Immunopharmacol 2023 (PMID 36989892), which found TA1 restored immune homeostasis (↓PD-1, ↓IL-6/IFN-γ, ↑IL-10) in lymphocytes from post-COVID patients — but this was a tiny (n=10), ex-vivo study (patients’ cells treated with TA1 in the lab, not a treatment trial), and the effect was strongest in the more severely affected. Treat as “promising hypothesis, not proven indication.”

Two honest negatives worth knowing (the “we tell you the failures too” part).

• Cystic fibrosis — the single-molecule claim that didn’t replicate. A high-profile 2017 paper (Romani et al., Nature Medicine 2017;23:590–600, PMID 28394330) proposed TA1 as a “potential potent single-molecule-based therapy” for CF that could partly correct the underlying CFTR chloride-channel defect and calm inflammation. The chloride-channel half did not hold up: independent labs — Tomati et al., JCI Insight 2018 (PMID 29415893, “devoid of activity on mutant CFTR”) and Armirotti et al., Sci Rep 2019 (PMID 31311979, reporting six independent labs unable to reproduce F508del-CFTR correction) — could not replicate the effect. Important nuance: the paper was not retracted, and the only formal amendment was a trivial Publisher Correction fixing an amino-acid sequence — not a correction of the science. The dispute played out through Matters-Arising correspondence and independent papers; what survived is, at most, a possible anti-inflammatory benefit, not a CFTR corrector.
• Hepatitis C — overtaken by better drugs. TA1 showed early promise combined with interferon but never confirmed a Phase 3 in non-responders (Sherman et al., Hepatology 1998, PMID 9537454, was modest/inconclusive). It’s now essentially moot: since sofosbuvir (approved Dec 2013), direct-acting antivirals cure >95% of hep C (WHO), so there’s no role left for TA1 there. This is a useful reminder that “promising peptide” and “still the right tool a decade later” are different questions.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs in the US. This is not medical advice. Consult a qualified physician before beginning any protocol.

The protocol clinical trials actually used: and what the community runs.

• Dose: 1.6 mg subcutaneous, twice per week. (Originally calculated as 900 µg/m² body-surface area; rounded to 1.6 mg for most adults.) This dose is essentially universal across the 30+ trials and is what one practitioner describes as the clinical standard.
• Frequency: Twice weekly — no fasting requirement, no time-of-day restriction. Many users dose on Monday and Thursday or similar split.
• Duration:
  • General immune support / vaccine season: 4–8 weeks with breaks.
  • Chronic viral / post-viral / chronic infection: 6–12 months continuously.
  • Cancer-adjuvant / immunosenescent rebuild (60+, diabetics): longer continuous courses, often 6+ months.

The dose barely moves — frequency is the lever. One practitioner’ masterclass framing is that TA1 dosing is frequency-tiered, not dose-tiered: the amount stays ~1.5–1.6 mg and you change how often you inject based on how active the problem is:

Tier	Situation	Protocol
1 — general / seasonal	Prophylaxis; travel, stress, cold-and-flu season	1.5 mg twice weekly, 4–8-week blocks
2 — active issue	Older adult not responding, long COVID, an infection you’re working to clear	1.6 mg 3–5× per week (same dose, tighter timing)
3 — clinical / oncology	Cancer-adjuvant, hospital settings	~1.5 mg daily, in short blocks

By purpose: longevity 1.5–1.6 mg 2×/wk · postviral / T-cell exhaustion / long COVID / EBV 1.5 mg 2×/wk for up to 24 weeks · recurrent / sinus infections 1.5 mg 2×/wk for 8–12 weeks · selected (non-flaring) autoimmune 1.5 mg for 12–24 weeks · post-surgery healing stack 1.5 mg 2×/wk. There is a ceiling: above ~1.5–2 mg does nothing extra, and dosing more frequently at higher amounts is just waste.

Timeline — judge by the pattern, not injection day. Plasma half-life is short (reported under ~3 hours), so there is no acute effect on injection day — no buzz, no performance lift. Weeks 1–4 are a quiet immune “retraining” that accumulates; weeks 4–12 bring fewer colds, faster recovery, and often an energy lift. If you’re already sick, TA1 shortens the illness (e.g. a 3–5-day cold to 1–2 days) rather than aborting it. Most people feel nothing acute, and that’s normal.

How to tell it’s working. Subjectively: frequency, severity, and duration of illness drop; better daily energy, recovery, sleep, and stress resilience. Objectively, track CBC, hs-CRP (the most useful single marker), a metabolic and lipid panel, vitamin D, and ferritin — retest no sooner than ~3 months apart. Optimize vitamin D alongside TA1: low vitamin D undercuts the response, and the two work hand-in-hand for immune function.

Reconstitution math. TA1 typically ships as 5 mg or 10 mg lyophilized vials. For a 10 mg vial reconstituted with 3.125 mL bacteriostatic water, you get 3.2 mg/mL — and 1.6 mg = 0.5 mL = 50 units on a U-100 insulin syringe. Easier math if you reconstitute a 5 mg vial with 3.125 mL bac water → 1.6 mg/mL → 1.6 mg = 1 mL = 100 units (the full syringe). Reconstituted, store in the fridge. Inject water down the side of the vial, swirl — don’t shake. (one practitioner uses a simpler round-number fill — 2 mL into a 5 mg vial → 1.6 mg = 64 units, or 2 mL into a 10 mg vial → 1.6 mg = 32 units — either fill works; it’s just concentration bookkeeping.) Inject SubQ into belly fat, 29–31 gauge — no advantage to IM. One practical heads-up: TA1 stings noticeably going in (more sting than GHK-Cu, though less bruising), so rotate sites.

Cycling and benefit duration. Unlike BPC-157 (a heal-and-done peptide), TA1’s benefits are temporary. When you stop, the immune support fades over weeks because the underlying thymic decline hasn’t reversed. The framing that follows from this is honest: TA1 is maintenance support for a system that has lost capacity, not a one-time fix. The good news is there’s no classical desensitization — no published tolerance, downregulation, or diminishing returns with continuous use, and no safety concern with staying on. Practical cycle patterns: 4–8 weeks on around a specific risk window, or 8 on / 4 off, or 12 on / 4 off; acute issues stay on 12–24 weeks; chronic-disease settings can run continuous low-dose until healed. On stopping there is no crash, no rebound, no withdrawal — the peptide clears the blood within a day and the immune retraining fades gradually, with carryover of weeks to months (no taper needed).

Audience-specific dosing posture. Per the TEST-trial subgroup data: older adults (60+), diabetics, the immune-compromised, and those with documented immunosenescence are the strongest indications. Healthy adults under 60 with normal immune function should be more conservative — the mechanism doesn’t have as much to do for an already-functional immune system, and the under-60 sepsis subgroup showed harm rather than benefit when the system was already hyper-active. This is the rare peptide where age-specific guidance matters.

Stacking. TA1 is the immune-system installment of what some practitioners call the “four-peptide forever stack”: MOTS-c (metabolic / ATP), Epithalon (genetic / telomere), BPC-157 (repair), and TA1 (immune intelligence). Each addresses a different layer of age-related decline; together they cover the three-failures spine (inflammation, insulin resistance, ATP shortage) plus the immune-surveillance overlay. KLOW (BPC-157 + TB-500 + KPV + GHK-Cu) provides some immune support via KPV but is not a TA1 substitute: different mechanism, different target. The natural Alyve pairing today is TA1 + KLOW = immune foundation + tissue repair full-stack (when TA1 is in catalog).

Purpose-built pairings:

• Active infection → LL-37 + TA1. This is the single most-cited pairing for an active infection. LL-37 is directly antimicrobial — it attacks the pathogen — while TA1 restores the immune competence that let the infection take hold in the first place; run together from the start for a “1 + 1 = 3” effect, and TA1’s balancing arm also keeps LL-37’s pro-inflammatory potential in check. Note TA1 itself is only a weak / indirect anti-inflammatory, which is why it pairs rather than competes with LL-37 (antimicrobial) and KPV (strong direct anti-inflammatory).
• Post-surgery / injury → BPC-157 + TB-500 at the time of injury, with TA1 layered alongside. BPC-157/TB-500 drive the tissue repair; TA1 keeps immune function from becoming the rate-limiter on recovery and covers hospital-acquired infection risk. The older or more immune-compromised the patient, the more that immune layer earns its place. See Wolverine (BPC-157 + TB-500).
• With a GLP-1 → fine, often helpful. TA1 can be run alongside semaglutide or tirzepatide (even a micro-dose) with no interaction issue; for an immune-issue patient a tirzepatide micro-dose is a reasonable metabolic/anti-inflammatory complement while TA1 does the immune work.
• In sensitive autoimmune patients, add one new peptide at a time. Don’t introduce six or seven at once — you won’t be able to attribute effects, and autoimmune patients tend to react to new inputs. (For general immune support in a non-sensitive person, a broader stack is fine.)

The TA1 vs LDN conceptual distinction (both immune modulators, different jobs). Low-Dose Naltrexone and TA1 are both used as immune modulators in autoimmune protocols, and the question “do I need both?” comes up. Different jobs: LDN calms the inflammatory storm in the short-to-medium term — reduces active cytokine output (TNF-α, IL-6, IL-1β) via endorphin-rebound signaling on immune cells, and dampens microglial-driven neuroinflammation via TLR4 antagonism. TA1 retrains the immune system in a deeper, slower-acting way — modulates T-cell maturation and function, restores Treg balance, reduces autoimmune aggression without globally suppressing necessary immune defense. Together they create comprehensive immune balance for severe / multi-condition autoimmune patients. Not redundant. The typical stack ladder for the autoimmune-on-GLP-1 patient: GLP-1 (foundation) → LDN at weeks 1–4 → BPC-157 + KPV at weeks 4–8 (gut-barrier) → TA1 at weeks 8–12 for severe / multi-condition cases. See Low-Dose Naltrexone (LDN) — the immune-modulation bridge for autoimmune patients on GLP-1s for the full stack architecture.

Side effects & management

TA1’s safety record is one of the cleanest in the entire peptide space. Across ~11,000 subjects in 30+ trials over multiple decades, the consistent finding is no serious adverse events attributable to TA1 alone. The most common reported effect is mild injection-site reactions (redness, minor irritation) — that’s it. As one practitioner puts it: “arguably one of the safest therapeutic molecules ever studied in history. LD50 is so astronomically high. Why? Because it’s not a foreign chemical — it’s you.”

Two hard contraindications — both serious.

Contraindication 1 — Organ transplant recipients on immunosuppression. TA1 is a labeled contraindication in transplant patients on immunosuppressive therapy (tacrolimus, cyclosporin, mycophenolate). The mechanism is a direct collision: tacrolimus and cyclosporin work by suppressing T-cell activation to prevent graft rejection; TA1 activates T-cells to recognize co-alloantigens more effectively. The two therapies are mechanistically opposed — TA1 specifically enhances the same T-cell machinery that identifies foreign tissue as foreign. In a transplant recipient, that enhanced recognition is the transplant rejection pathway. This is not theoretical overcaution; it is a collision of the drugs’ primary mechanisms.

Contraindication 2 — PD-1 / PD-L1 / CTLA-4 checkpoint-inhibitor cancer immunotherapy — outside oncologist supervision. A 2026 case report (Clinical Case Reports, PMID 41669704) documented a 29-year-old nasopharyngeal-carcinoma patient who developed severe multi-system immune-related adverse events within ~48 hours of receiving TA1 near PD-1 blockade (sintilimab): high fever, rash and facial edema, interstitial pulmonary edema, acute liver injury, coagulopathy, multi-organ failure. He recovered on high-dose steroids and later tolerated the PD-1 drug without TA1. The mechanism is straightforward: checkpoint inhibitors take the brakes off T-cell activation; TA1 puts the pedal down on T-cell maturation and activation; together you can get the immune system attacking healthy tissue (the same class of multi-system iAEs that already limits checkpoint-inhibitor monotherapy). If you are on cancer immunotherapy, this is a conversation with your oncologist before considering TA1: not after.

The genuinely unsettled part (why the science isn’t one-directional). The evidence here actually points in both directions, and honesty requires showing both. In mice, TA1 has been reported to protect against checkpoint-inhibitor gut damage: Renga et al., Life Science Alliance 2020;3(10):e202000662 prevented anti-CTLA-4 intestinal immunopathology through an IDO1-dependent tolerogenic pathway while preserving the anti-tumor CD8+ attack (the protection disappeared in IDO1-knockout mice). That’s the optimistic “TA1 could make immunotherapy safer” story some educators cite. But it is mouse-only, from a long-time TA1-proponent group, and not clinically established — and it sits directly against the human case report above. The correct read for now: TA1 + checkpoint inhibitor is investigational for both efficacy and safety (see the 2026 Frontiers in Immunology review, DOI 10.3389/fimmu.2026.1762151); the animal-protective finding does not license a DIY stack, and the real-world signal is a severe adverse event. Keep the contraindication; don’t let the preclinical promise soften it.

The subgroup-harm signal under 60. Per the TEST sepsis trial, under-60 patients showed worse outcomes than placebo. The mechanistic interpretation: TA1 modulates immune systems; if yours is already over-activated (acute hyper-inflammatory states, certain autoimmune flares, septic shock in a young healthy adult), adding more activation can make things worse. Healthy under-60 adults should match dose, duration, and indication carefully — the audience for “compensating for a declining thymus” is meaningfully older or metabolically compromised.

The severe-autoimmune-flare “whiplash” caution. This is the same theme at the clinical bedside. In a severe active autoimmune flare — new-onset type-1 diabetes, autoimmune hepatitis, vasculitis — introducing TA1 mid-flare can cause more harm than good; during a hard flare almost any immune input can worsen it, and TA1 is one of them. The practical sequencing practitioners describe: calm the flare first (e.g. KPV for direct anti-inflammatory action, or a mitochondrial peptide), get it to a manageable baseline, then bring TA1 in for the long-haul rebalancing. This applies to roughly the worst ~10% of autoimmune cases; for milder, non-flaring autoimmune presentations TA1 is generally fine and can help restore balance. It’s a genuine “modulator, not booster” corollary — the same reason it helps a dysregulated immune system is why it can destabilize one that’s already in overdrive.

Otherwise: mild injection-site irritation, occasional fatigue/dizziness early in protocol (resolve over the first 1–2 weeks). No tachyphylaxis. No documented withdrawal syndrome.

Use in dogs and cats (vet practice)

Thymosin Alpha-1’s mechanism — T-cell maturation and immune-system regulation rather than immune suppression — fits a specific companion-animal patient profile cleanly: pets with autoimmune-style presentations (immune-mediated hemolytic anemia, immune-mediated polyarthritis, atopic dermatitis with autoimmune components), chronic infections in immunocompromised pets, and cancer-supportive care alongside conventional veterinary oncology. The human evidence base for TA1 includes substantial work in cancer-supportive contexts (well-documented across hepatitis B/C antiviral combinations and as a vaccine adjuvant in elderly populations); the mechanism transfers to vet oncology on biological grounds, though formal vet trial data is limited. The exceptional safety profile transfers as well — ~11,000 human subjects across 30+ trials with no serious AEs attributable to TA1 alone is the cleanest safety record in the immune-modulating peptide cluster, and that mechanism-level safety should reasonably extrapolate to companion-animal use. The hard contraindication carries over: do not stack TA1 with checkpoint-inhibitor cancer immunotherapy in pets undergoing such treatment — the immune-related adverse-event risk that limits the combination in human oncology applies cross-species. Work with a veterinarian (ideally one familiar with integrative oncology if cancer-supportive use is the indication). See Peptides for Pets for the broader companion-animal framework.

Regulatory status

Not FDA-approved in the US for any indication. Orphan-drug designations for melanoma, hepatocellular carcinoma, and hepatitis B: designations are NOT approvals. Approved as Zadaxin / thymalfasin in 30+ countries for hep B, hep C, immune support during cancer therapy, and vaccine adjuvant use in elderly populations.

US compounding timeline:

• September 2024: FDA removed TA1 from compounding Category 2 (“do not compound”).
• December 2024: FDA advisory committee voted against putting TA1 on the compounding list (which would have allowed prescribed compounded TA1 via 503A pharmacies).
• July 2026: Next FDA meeting could shift the status further. This is the regulatory date to watch.
• Currently sold legally in the US as a research chemical, “not for human consumption.”

Note on one practitioner’s framing: he describes TA1 as “FDA approved as an adjunctive therapy for diseases like melanoma and hep B.” That overstates the current US status — those are orphan-drug designations, not approvals. One practitioner’ more precise framing is what this article uses.

Where to buy

Thymosin Alpha-1 is now available from US Pure Peptides — the primary OHM vendor for TA1. Use code OHM20 for 20% off. USP carries a 10mg lyophilized vial with ISO 17025-accredited third-party COA; US-manufactured in West Palm Beach, FL, HPLC + Mass Spec verified. Also available at BioLongevity with code OHM-15 for 15% off. Not in Alyve’s current catalog.

TA1 has more human safety data behind it than nearly any other peptide in the longevity cluster (~11,000 subjects, 30+ trials, decades of post-marketing Zadaxin use abroad). Independent gray-market peptide audits keep finding roughly 1 in 4 vials underdosed, mislabeled, or contaminated (often with leftover TFA salt from synthesis), and most carry no COA at all. Both USP and BioLongevity answer that with verified COA and ≥99% purity — USP’s ISO 17025-accredited testing is the higher-standard option.

Practical pairing while on TA1: combine with KLOW from Alyve (BPC-157 + TB-500 + KPV + GHK-Cu) — KPV provides a complementary anti-inflammatory / NF-κB-inhibition layer. Use OHM-15 at Alyve: buying 3 vials of KLOW in one purchase gets you over 30% off retail.

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.

Field	Value
Molecular formula	C129H215N33O55 (PubChem CID 16130571)
Average MW	3108.32 g/mol
CAS	62304-98-7
Sequence	Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (N-acetylated 28-mer; Ac-Ser-…-Asn-OH). N-terminal acetylation is required for activity/stability
HPLC purity criterion	RP-HPLC (C18, 0.1% TFA water/ACN, 15–35% B over 30 min, 40°C), UV 214 nm; ≥98% by area; anion-exchange as orthogonal check (pI 4.2)
MS identity	ESI-MS multi-charge [M+3H]3+ 1037.1, [M+4H]4+ 778.1, [M+5H]5+ 622.7; MALDI-TOF [M+H]+ ~3109; Edman confirms Ac-Ser N-terminus
Counterion / net peptide	Highly acidic, net ~−9 at pH 7, pI 4.2; TFA or acetate counter-ion reported for accurate weighing; peptide content by quantitative AAA
Storage / reconstitution	Lyophilized at −20°C/−80°C long-term, desiccated, light-protected; reconstitute 1.6 mg vial in 1.0 mL sterile/bacteriostatic water, swirl not shake; do not refreeze; bacteriostatic = up to 7 days at 2–8°C
Degradation / stability	Instability index ~48.7 (classified unstable); pathways = Asp-Pro hydrolysis, Asn/Gln deamidation, aggregation; most stable at pH 4–5; degradation ~doubles per +10°C

Primary-literature citation leads (PeptideBiologix; confirm before citing): hep-B meta-analysis (13 RCTs, n=1,049); HCC + TACE RCT (n=398, OS 26.3 vs 18.7 mo); NSCLC meta-analysis (7 RCTs, n=788); sepsis RCT (n=361, 28-day mortality 38.9%→27.8%, p=0.037). Author/-level citations were NOT given in the raw capture — pin each before use.

Sources

• balanced-mainstream-honest source. Mechanism (TLR2 + TLR9 simultaneous), thymic decline metrics, clinical wins (hep B, vaccine enhancement, NSCLC, gastric cancer), the TEST sepsis trial negative + under-60 harm signal, PD-1 contraindication 2026 case report, dosing protocol, ~11,000-subject safety record, FDA regulatory timeline.
• one practitioner’ longer “masterclass” companion. Source of the frequency-tiered dosing (Tier 1/2/3 + by-purpose), the dose ceiling (~1.5–2 mg), the timeline / biomarker-monitoring / vitamin-D-synergy guidance, the cycling patterns (4–8 on, 8/4, 12/4) and no-desensitization framing, the severe-autoimmune-flare “whiplash” caution, the LL-37 active-infection pairing + BPC/TB-500 post-surgery layering, reconstitution (2 mL fill) + injection-sting note, and the cystic-fibrosis 2017 reproducibility failure / hep-C obsolescence / checkpoint-colitis-protection framing. Also cites broader post-marketing exposure figures (~37 countries, >600,000 patients — a different denominator from the 11,000-trial-subject figure).
• funcmed-deep mechanism source. Disease-by-disease cluster (Hashimoto’s, hep B/C, microglia / Alzheimer’s, HPA / cortisol resistance, Parkinson’s, MS, cancer survival), three-failures-framework integration, endogenous-peptide-can’t-be-patented framing. Note: one practitioner’s “89% survival increase in lung/breast/prostate” claim and the “FDA-approved adjunctive for melanoma + hep B” framing are flagged for verification and replaced with one practitioner’ more conservative precise numbers.
• four-peptide forever stack (MOTS-c + Epithalon + BPC-157 + TA1) rationale + synergistic-stack disease-axis breakdown.
• TA1 graded A/green PRIMARY immune + SECONDARY heal-recover; flagged as strongest catalog-expansion candidate.
• confirmed TA1 is NOT in current 15-SKU catalog.

Verification pass 2026-07-07 (from the one practitioner masterclass digest) newly pinned: discovery history (PNAS 1977, via DOI 10.1073/pnas.74.2.725; co-author is Teresa L. Low); mechanism primaries (Romani Blood 2004 PMID 14982877 + 2006 PMID 16741252 — and the “TLR2=attack/TLR9=brake” split corrected, since TLR9 feeds both arms); complement-phagocytosis (Serafino J Innate Immun 2014 PMID 23797159); T-cell-exhaustion/COVID (Liu Clin Infect Dis 2020 PMID 32777028, retrospective n=76); long-COVID (Minutolo Int Immunopharmacol 2023 PMID 36989892, n=10 ex-vivo); CF replication failure (Romani Nat Med 2017 PMID 28394330; Tomati 2018 PMID 29415893; Armirotti 2019 PMID 31311979 — not retracted, only a Publisher Correction); plasma half-life <3 h (PMID 10027483); the 2026 PD-1+TA1 iAE case report → PMID 41669704; the mouse checkpoint-colitis-protection counter-evidence (Renga Life Sci Alliance 2020); adjuvant cancer trials (melanoma Maio JCO 2010 PMID 20194853 — P=0.08, non-significant; NSCLC Zhang Chin Med J 2021 PMID 34732663, propensity-matched).

Related: BPC-157 · MOTS-c · Epithalon · SS-31 (Elamipretide) · Kisspeptin · KLOW.